{"id":"https://openalex.org/W2005419086","doi":"https://doi.org/10.1161/01.cir.91.2.403","title":"SC-54684A: An Orally Active Inhibitor of Platelet Aggregation","display_name":"SC-54684A: An Orally Active Inhibitor of Platelet Aggregation","publication_year":1995,"publication_date":"1995-01-15","ids":{"openalex":"https://openalex.org/W2005419086","doi":"https://doi.org/10.1161/01.cir.91.2.403","mag":"2005419086","pmid":"https://pubmed.ncbi.nlm.nih.gov/7805244"},"language":"en","primary_location":{"id":"doi:10.1161/01.cir.91.2.403","doi":"https://doi.org/10.1161/01.cir.91.2.403","is_oa":false,"landing_page_url":"https://doi.org/10.1161/01.cir.91.2.403","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088786123","display_name":"Nancy S. Nicholson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Nancy S. Nicholson","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021720106","display_name":"Susan G. Panzer\u2010Knodle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Susan G. Panzer-Knodle","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027510923","display_name":"Anita K. Salyers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Anita K. Salyers","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113544588","display_name":"Beatrice B. Taite","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Beatrice B. Taite","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017768573","display_name":"James A. Szalony","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"James A. Szalony","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003083963","display_name":"Neal F. Haas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Neal F. Haas","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041227121","display_name":"Lucy W. King","orcid":"https://orcid.org/0009-0004-5994-9664","observed_orcids":["https://orcid.org/0009-0004-5994-9664"]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Lucy W. King","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058401100","display_name":"Jeffery A. Zablocki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Jeffery A. Zablocki","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109562877","display_name":"Bradley T. Keller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Bradley T. Keller","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003567549","display_name":"Kay O. Broschat","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Kay Broschat","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011381776","display_name":"V. Wayne Engleman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"V. Wayne Engleman","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111973790","display_name":"Marc F. Herin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Marc Herin","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046470141","display_name":"Phillipe Jacqmin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Phillipe Jacqmin","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032131706","display_name":"Larry P. Feigen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1295346377","display_name":"Monsanto (United States)","ror":"https://ror.org/00j83wy46","country_code":"US","type":"company","lineage":["https://openalex.org/I1295346377"]},{"id":"https://openalex.org/I137982388","display_name":"Janssen (Belgium)","ror":"https://ror.org/04yzcpd71","country_code":"BE","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I137982388"]}],"countries":["BE","US"],"is_corresponding":false,"raw_author_name":"Larry P. Feigen","raw_affiliation_strings":["From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","Janssen Research Foundation (P.J.), Beerse, Belgium","Monsanto Corporate Research (W.E.), St Louis, Mo","the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Departments of Cardiovascular Diseases Research (N.S.N., S.G.P.-K., A.K.S., B.B.T., J.A.S., N.F.H., L.W.K., L.P.F.) and Chemical Research (J.A.Z.), Searle, Skokie, Ill; the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo; Monsanto Corporate Research (W.E.), St Louis, Mo; the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium; and Janssen Research Foundation (P.J","institution_ids":[]},{"raw_affiliation_string":"Janssen Research Foundation (P.J.), Beerse, Belgium","institution_ids":["https://openalex.org/I137982388"]},{"raw_affiliation_string":"Monsanto Corporate Research (W.E.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]},{"raw_affiliation_string":"the Department of Pharmacokinetics and Drug Metabolism (M.H.), Lilly Mont-Saint-Guibert Development Center, Mont St Guibert, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Departments of Cardiovascular Diseases (B.T.K.) and Monsanto Corporate Research (K.B.), St Louis, Mo","institution_ids":["https://openalex.org/I1295346377"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":8.3209,"has_fulltext":false,"cited_by_count":64,"citation_normalized_percentile":{"value":0.98216056,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"91","issue":"2","first_page":"403","last_page":"410"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.8598999977111816,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.8598999977111816,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.06880000233650208,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11064","display_name":"Antiplatelet Therapy and Cardiovascular Diseases","score":0.047600001096725464,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fibrinogen-receptor-antagonists","display_name":"fibrinogen receptor antagonists","score":0.8510000109672546},{"id":"https://openalex.org/keywords/platelet-inhibition","display_name":"platelet aggregation inhibition","score":0.7760000228881836},{"id":"https://openalex.org/keywords/oral-prodrug","display_name":"oral prodrug","score":0.6060000061988831},{"id":"https://openalex.org/keywords/antiplatelet-drugs","display_name":"antiplatelet agents","score":0.7110000252723694},{"id":"https://openalex.org/keywords/fibrinogen-binding","display_name":"fibrinogen binding","score":0.8069999814033508},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.8640000224113464},{"id":"https://openalex.org/keywords/bleeding-time","display_name":"bleeding time","score":0.7319999933242798},{"id":"https://openalex.org/keywords/thromboprophylaxis","display_name":"thromboprophylaxis","score":0.6570000052452087}],"concepts":[{"id":"https://openalex.org/C164144092","wikidata":"https://www.wikidata.org/wiki/Q6587033","display_name":"Vitronectin","level":4,"score":0.8582139611244202},{"id":"https://openalex.org/C2779036427","wikidata":"https://www.wikidata.org/wiki/Q381899","display_name":"Fibrinogen","level":2,"score":0.7386554479598999},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6309503316879272},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.6144809722900391},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5860012173652649},{"id":"https://openalex.org/C89560881","wikidata":"https://www.wikidata.org/wiki/Q101026","display_name":"Platelet","level":2,"score":0.5634387135505676},{"id":"https://openalex.org/C86492073","wikidata":"https://www.wikidata.org/wiki/Q413766","display_name":"Fibronectin","level":3,"score":0.46614208817481995},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4063681960105896},{"id":"https://openalex.org/C195687474","wikidata":"https://www.wikidata.org/wiki/Q409715","display_name":"Integrin","level":3,"score":0.3275708258152008},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.30758219957351685},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.27742576599121094},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27594852447509766},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.13114842772483826}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001550","descriptor_name":"Benzamidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002250","descriptor_name":"Carbon Radioisotopes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004285","descriptor_name":"Dogs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005340","descriptor_name":"Fibrinogen","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010975","descriptor_name":"Platelet Aggregation Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010975","descriptor_name":"Platelet Aggregation Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010980","descriptor_name":"Platelet Membrane Glycoproteins","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012680","descriptor_name":"Sensitivity and Specificity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013927","descriptor_name":"Thrombosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1161/01.cir.91.2.403","doi":"https://doi.org/10.1161/01.cir.91.2.403","is_oa":false,"landing_page_url":"https://doi.org/10.1161/01.cir.91.2.403","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},{"id":"pmid:7805244","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7805244","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W137524307","https://openalex.org/W206174948","https://openalex.org/W286388493","https://openalex.org/W619423027","https://openalex.org/W1141074930","https://openalex.org/W1481395580","https://openalex.org/W1518372943","https://openalex.org/W1545341742","https://openalex.org/W1552411463","https://openalex.org/W1559044733","https://openalex.org/W1594038744","https://openalex.org/W1984258208","https://openalex.org/W2012330153","https://openalex.org/W2040041623","https://openalex.org/W2040619646","https://openalex.org/W2053917461","https://openalex.org/W2055126125","https://openalex.org/W2066279385","https://openalex.org/W2068283959","https://openalex.org/W2072228531","https://openalex.org/W2077459776","https://openalex.org/W2080462641","https://openalex.org/W2085013636","https://openalex.org/W2092823124","https://openalex.org/W2118773555","https://openalex.org/W2309482606","https://openalex.org/W2340562441","https://openalex.org/W2341935027","https://openalex.org/W2525818865","https://openalex.org/W2795929191","https://openalex.org/W4324114048"],"related_works":["https://openalex.org/W2040619646","https://openalex.org/W2006926927","https://openalex.org/W2069759788","https://openalex.org/W2068283959","https://openalex.org/W2118773555","https://openalex.org/W1844788602","https://openalex.org/W1941168283","https://openalex.org/W2039404414","https://openalex.org/W2068916210","https://openalex.org/W1981049864"],"abstract_inverted_index":{"BACKGROUND:":[0],"Intravenous":[1],"therapy":[2],"has":[3,310],"been":[4,52],"shown":[5,289],"to":[6,81,91,103,126,135,140,154,162,171,197,246,290,302],"be":[7,22,291],"beneficial":[8],"in":[9,56,88,205,285,313],"the":[10,31,60,111,121,151,192,208,215,221,234,241,247,250,260,268,272],"prevention":[11],"of":[12,64,78,86,97,110,123,174,233,256,271,306],"acute":[13],"platelet-associated":[14],"thrombotic":[15],"events.":[16],"However,":[17],"orally":[18,46,61,213,265,280],"active":[19,47,62,112,193,216,237,248,251,273,281],"agents":[20],"would":[21],"advantageous":[23],"for":[24,40],"chronic":[25],"therapy.":[26],"Fibrinogen":[27],"receptor":[28],"antagonists":[29],"block":[30],"fibrinogen/platelet":[32],"interaction":[33],"and":[34,67,84,94,101,137,143,176,184,214,266,309],"thus":[35],"inhibit":[36],"a":[37,65,166,254,292,303],"step":[38],"required":[39],"thrombus":[41],"formation.":[42],"To":[43],"date,":[44],"no":[45],"fibrinogen":[48,69,144,295],"binding":[49,70,80,122,152,161,170,296],"inhibitors":[50],"have":[51],"characterized.":[53],"SC-54684A,":[54,278],"now":[55,284],"clinical":[57,286],"trial,":[58,287],"is":[59,288],"prodrug":[63,210,235,242,261],"potent":[66],"specific":[68,294],"antagonist.":[71],"METHODS":[72],"AND":[73],"RESULTS:":[74],"We":[75],"measured":[76],"inhibition":[77,85],"125I-fibrinogen":[79],"activated":[82],"platelets":[83],"aggregation":[87,179,301],"platelet-rich":[89],"plasma":[90],"selected":[92],"agonists":[93],"showed":[95,239],"IC50s":[96],"1.0":[98],"x":[99,105],"10(-8)":[100,106],"3":[102],"7":[104],"mol/L,":[107],"respectively.":[108],"Specificity":[109],"moiety":[113,194,217,238,252,274],"was":[114,148,165,180,187,195,211,218,225,243,262,275],"determined":[115],"by":[116,182],"studying":[117],"its":[118],"effect":[119,147],"on":[120,150],"(1)":[124],"neutrophils":[125,153],"interleukin":[127],"(IL)-1":[128],"beta-stimulated":[129],"endothelial":[130,133,156,159],"cells,":[131],"(2)":[132],"cells":[134,157],"fibronectin,":[136],"(3)":[138],"vitronectin":[139,142,175],"isolated":[141,172],"receptors.":[145],"No":[146],"observed":[149],"IL-stimulated":[155],"or":[158,236],"cell":[160],"fibronectin.":[163],"There":[164],"fivefold":[167],"separation":[168],"between":[169],"receptors":[173],"fibrinogen.":[177],"Collagen-induced":[178],"inhibited":[181],"80%,":[183],"bleeding":[185],"time":[186],"increased":[188],"approximately":[189,226],"2.5-fold":[190],"when":[191],"infused":[196],"steady":[198],"state":[199],"at":[200],"0.2":[201],"micrograms/kg":[202],"per":[203],"minute":[204],"dogs.":[206],"When":[207,259],"ester":[209],"given":[212,219],"intravenously,":[220,267],"oral":[222],"systemic":[223,269],"activity":[224],"20%.":[227],"Pharmacokinetic":[228],"analysis":[229],"after":[230],"intravenous":[231],"infusion":[232],"that":[240,298],"rapidly":[244],"converted":[245],"moiety;":[249],"had":[253],"t1/2":[255],"6.5":[257],"hours.":[258],"administered":[263],"both":[264],"availability":[270],"62%.":[276],"CONCLUSIONS:":[277],"an":[279],"antiplatelet":[282],"drug":[283],"potent,":[293],"inhibitor":[297],"blocks":[299],"platelet":[300],"wide":[304],"variety":[305],"known":[307],"stimuli":[308],"good":[311],"bioavailability":[312],"animals.":[314]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}